Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Other, SGLT2i Apr 06 | 2021AZ and Mass Gen Hospital Collaborate with AMAZE Platform; Ionis to Reduce Akcea Workforce by ~70%; Galectin Launches Website for NAVIGATE Trial in NASH; Blue Shield of California Adds Two New Services to Wellvolution PlatformPurchase Blast
$599
Posted in: GLP-1RA Apr 05 | 2021Thoughts on Novo/Mylan (Viatris) Dismissing Their Victoza Patent Dispute; Did Viatris Just Abandon Its Generic?Purchase Blast
$599
Posted in: Glucose Monitoring Apr 05 | 2021Dexcom and Welldoc Expand Partnership for T2DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Mar 30 | 2021Novo Initiates Ph3 Sema NASH Trial; BrightInsight Secures $101M in Series C Funding; Amarin Receives EC Approval for Vazkepa CV Risk Reduction; Glytec Updates Glucommander Insulin Dosing Algorithm; Voluntis FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Mar 29 | 2021New Medtronic/InPen MDI Basal+Bolus Advisement Connected SystemPurchase Blast
$599
Posted in: GLP-1RA Mar 26 | 2021Novo’s Oral Sema Alzheimer’s Studies Posted on CT.gov; Saxenda Receives Positive CHMP OpinionPurchase Blast
$599
Posted in: Dual/triple agonist, Other, SGLT2i Mar 25 | 2021Meet AZ Management Investor Event HighlightsPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other Mar 23 | 2021Novo STEP 4 Sema Obesity Results @ ENDO 2021; Oramed Second Oral Insulin Ph3 Trial Update; Dexcom Promotes Jereme Sylvain to CFO; vTv Granted New Patent for TTP399Purchase Blast$599
Posted in: Glucagon, Other Mar 22 | 2021Zealand's Dasiglucagon Approved; March 22-25 CHMP Agenda; Fractyl Enrolls First Patient in T2DM Study; Twist Bioscience Announces Positive Preclinical DataPurchase Blast
$599
Posted in: Insulin Delivery Mar 20 | 2021Omnipod 5 Pivotal Data Meets the Bar and Leaves Room for Further InnovationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Mar 19 | 2021Biocorp Partners to Integrate Mallya into Diabeloop AID System; vTv Initiates New TTP399 Study; Adocia and Sigilon Q4 '20 Earnings UpdatesPurchase Blast$599
Posted in: Glucose Monitoring, Other, SGLT2i Mar 18 | 2021New Implantable CGM Study from Indigo; Gilead/Novo Expand NASH Collaboration; Metacrine Q4 '20 Earnings Update; Cytokinetics to Present GALACTIC-HF Analysis at ACC 2021Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Mar 17 | 2021Bigfoot Recieves $57M in Financing; ACC/Novo Partner for T2DM/CVD HCP Education; Amazon Care Telehealth Program Launched NationwidePurchase Blast
$599
Posted in: Insulin Delivery Mar 17 | 2021Insulet to Host Investor Event Following Omnipod 5 Pivotal Data Presentation @ ENDO 2021Purchase Blast
$599
Posted in: Basal Insulin, SGLT2i Mar 16 | 2021Glooko Raises $30M Series D; AZ and BrightInsight Launch Digital Platform; Oramed Randomizes 25% of Patients in Ph3 Oral Insulin TrialPurchase Blast
$599
Posted in: Bolus Insulin Mar 15 | 2021MannKind to Participate in Medicare Part D Senior Savings ModelPurchase Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
